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triBACKGROUND Disrupting the costimulatory CD40-CD40L dyad reduces atherosclerosis, but can result in immune
suppression. The authors recently identiﬁed small molecule inhibitors that block the interaction between CD40 and
tumor necrosis factor receptor-associated factor (TRAF) 6 (TRAF-STOPs), while leaving CD40-TRAF2/3/5 interactions
intact, thereby preserving CD40-mediated immunity.
OBJECTIVES This study evaluates the potential of TRAF-STOP treatment in atherosclerosis.
METHODS The effects of TRAF-STOPs on atherosclerosis were investigated in apolipoprotein E deﬁcient
(Apoe/) mice. Recombinant high-density lipoprotein (rHDL) nanoparticles were used to target TRAF-STOPs
to macrophages.
RESULTS TRAF-STOP treatment of young Apoe/ mice reduced atherosclerosis by reducing CD40 and integrin
expression in classical monocytes, thereby hampering monocyte recruitment. When Apoe/ mice with established
atherosclerosis were treated with TRAF-STOPs, plaque progression was halted, and plaques contained an increase
in collagen, developed small necrotic cores, and contained only a few immune cells. TRAF-STOP treatment did
not impair “classical” immune pathways of CD40, including T-cell proliferation and costimulation, Ig isotype
switching, or germinal center formation, but reduced CD40 and b2-integrin expression in inﬂammatory monocytes.
In vitro testing and transcriptional proﬁling showed that TRAF-STOPs are effective in reducing macrophage
migration and activation, which could be attributed to reduced phosphorylation of signaling intermediates of
the canonical NF-kB pathway. To target TRAF-STOPs speciﬁcally to macrophages, TRAF-STOP 6877002 was
incorporated into rHDL nanoparticles. Six weeks of rHDL-6877002 treatment attenuated the initiation of
atherosclerosis in Apoe/ mice.
CONCLUSIONS TRAF-STOPs can overcome the current limitations of long-term CD40 inhibition in atherosclerosis
and have the potential to become a future therapeutic for atherosclerosis. (J Am Coll Cardiol 2018;71:527–42)
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TRAF = tumor necrosis factor
receptor-associated factor
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528A therosclerosis, the underlying causeof the majority of cardiovasculardiseases (CVDs), is a lipid-driven in-
ﬂammatory disease of the large arteries
(1–4). Although lipid-lowering drugs, such
as 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase inhibitors and the
novel proprotein convertase subtilisin/kexin 9
(PCSK9) inhibitors have helped to lower the
incidence of CVD (5), a substantial part of
the population still have CVD (6). Hence,
additional strategies to decrease the persis-
tent residual risk of CVD in the population
are needed. In conjunction with hyperlipid-
emia, activation of the immune system andSEE PAGE 543subsequent inﬂammation determines atherosclerosis
progression (2,3). Therefore, novel drug targets that
block atherosclerosis-associated inﬂammation have
great therapeutic potential. This was recently
demonstrated in the CANTOS (Canakinumab Antiin-
ﬂammatory Thrombosis Outcome Study) trial, in
which the anti-IL1b antibody canakinumab reduced
the incidence rate of the primary composite endpoint
of nonfatal myocardial infarction, nonfatal stroke, or
cardiovascular death (hazard ratio: 0.85; 95% conﬁ-
dence interval: 0.74 to 0.98; p ¼ 0.021) in patients
with a previous myocardial infarction and high resid-
ual inﬂammatory risk (7).
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or antibody-mediated inhibition of CD40 or CD40L
strongly reduces atherosclerosis in hyperlipidemic
mice (11–14). However, long-term inhibition of CD40
or CD40L results in immune suppression and/or
thromboembolic events, and is therefore not feasible
as a therapy (10,15,16).
Upon activation, CD40 recruits tumor necrosis
factor receptor-associated factors (TRAFs) to elicit
intracellular signaling (12). The C-terminal tail of
CD40 has a distal binding site that can bind TRAF2,
TRAF3, and TRAF5, and a proximal binding site for
TRAF6. Studies on mice with mutated CD40-TRAF
binding sites revealed that CD40-TRAF6 interactions
are important for atherosclerosis and restenosis
(12,17). CD40-TRAF2/3/5 interactions only play a mi-
nor role in these diseases, and are more required for
CD40-associated immunity (12,17).We recently identiﬁed and characterized small
molecule inhibitors (SMIs) that selectively block
CD40-TRAF6 interactions: TRAF-STOPs (18). We
found that several SMIs of the TRAF-STOP family
successfully ameliorated peritonitis, sepsis, diet-
induced obesity, and experimental autoimmune
encephalomyelitis by reducing inﬂammation,
without causing immune suppression (18–21). Here,
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529mode of action of 2 members of our TRAF-STOP
family (i.e., 6677002 and 6860766) and investigated
their potential for treatment of atherosclerosis.
METHODS
All experiments were approved by the local animal
experimentation ethics committees. C57Bl6, apoli-
poprotein E-deﬁcient (Apoe/) (C57Bl6 background),
CD40/, CD40-Traf wild type (Twt), CD40-T2/3/5/,
CD40-T6/, Cx3cr1egfp/Apoe/, and OTII mice
were purchased from Charles River Laboratories
(Wilmington, Massachusetts), the Jackson Laboratory
(Bar Harbor, Maine), or bred at a local animal facility
(Maastricht University, Amsterdam Medical Center,
Ludwig-Maximilians-University). Expanded methods
are available in the Online Appendix.
RESULTS
TRAF-STOP TREATMENT HAMPERS THE INITIATION
OF ATHEROSCLEROSIS. To investigate the effect of
TRAF-STOP treatment on the initiation of athero-
sclerosis, Apoe/ mice on a normal chow diet were
treated with TRAF-STOP 6877002, TRAF-STOP
6860766, or control at 10 mmol/kg/day by intraperi-
toneal injection for 6 weeks, starting at the age of
12 weeks, when no atherosclerotic plaques were
present (Figure 1A). Treatment did not affect body
weight, plasma cholesterol levels, hematologic pa-
rameters, peripheral blood leukocyte counts, or im-
mune cell distribution in blood and lymphoid
organs, and did not cause toxic effects in any of the
organs analyzed (Online Figure 1). TRAF-STOP
treatment reduced atherosclerotic plaque area in
the aortic arch by 47% (6877002) and 67% (6860766)
compared with control-treated mice (Figures 1B to 1D).
Aortas from TRAF-STOP–treated mice contained rela-
tively less ﬁbrous cap atheromata and, correspond-
ingly, a relative increase in early atherosclerotic
plaques (intimal xanthoma and pathological intimal
thickening), indicating a retarded initiation of
atherosclerosis (Figures 1C and 1D). Within the plaque,
the number of macrophages (Mac3þ), T cells (CD3þ),
and neutrophils (Ly6Gþ) signiﬁcantly decreased
after TRAF-STOP treatment (Figures 1E to 1G). No
changes were observed in the number of prolifer-
ating (Ki67þ) or apoptotic cells (TUNELþ) in the
plaque, or plaque smooth muscle cell (aSMAþ) or
collagen (Sirius Redþ) content (Online Figure 2).
Treatment with either of the 2 TRAF-STOPs thusretards early atherosclerosis development and gen-
erates atherosclerotic plaques that are low in in-
ﬂammatory cells.
TRAF-STOP TREATMENT PREVENTS THE PROGRESSION OF
ESTABLISHED ATHEROSCLEROSIS. Commonly, patients
start receiving treatment when advanced atheroscle-
rosis is already eminent. Therefore, we investigated
the effect of TRAF-STOP treatment on established
atherosclerosis in mice. Apoe/ mice were treated
with TRAF-STOP 6877002, TRAF-STOP 6860766, or
control at 10 mmol/kg/day for 6 weeks, starting at the
age of 22 weeks, when advanced atherosclerotic le-
sions were present in the aortic arch (Figure 2A).
Again, treatment did not affect body weight, plasma
cholesterol levels, metabolic or hematologic parame-
ters, leukocyte counts, or immune cell composition,
and did not cause abnormalities in any of the organs
investigated (Online Figures 3A to 3L). Remarkably,
TRAF-STOP treatment halted the progression of
established atherosclerosis, as total atherosclerotic
plaque area was reduced compared with control-
treated mice in both the aortic arch and aortic root
(Figure 2B, Online Figure 3M). After treatment with
TRAF-STOP 6877002 or 6860766, atherosclerotic
plaques exhibited a stable plaque phenotype.
Macrophage number and macrophage proliferation
(Online Figure 3N) were decreased, and plaques
featured smaller necrotic cores (Figures 2C to 2E).
Plaques had fewer Ly6Gþ neutrophils (2.4  0.6 per
plaque [control] vs. 0.8  0.3 per plaque [6877002;
p < 0.05] vs. 1.2  0.2 per plaque [6860766; p ¼ 0.06]),
fewer CD3þ T cells (4.8  0.7 per plaque [control] vs.
1.6  0.3 per plaque [6877002] vs. 2.3  0.3 per plaque
[6860766]; p < 0.05), and had an increase in collagen
(Figure 2F) and aSMAþ smooth muscle cell content
(2.9  0.4% [control] vs. 7.2  1.2% [6877002] vs.
8.0  1.5% [6860766]; p < 0.05).
These results show that TRAF-STOPs 6877002 and
6860766 attenuate the progression of existing
atherosclerotic plaques and induce plaque
stabilization.
TRAF-STOP TREATMENT REDUCES LEUKOCYTE
RECRUITMENT. Although TRAF-STOP treatment did
not result in changes in immune cell composition or
composition of the hematopoietic stem and progeni-
tor cell population (Online Figure 4), ﬂow cytometry
revealed that the classical, but not the non-classical
monocyte population exhibited a decrease in activa-
tion markers. TRAF-STOP treatment reduced the fre-
quency of CD40high classical monocytes, as well as the
FIGURE 1 TRAF-STOP Treatment Inhibits the Development of Atherosclerosis
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531overall surface expression of CD40 (Figures 3A to 3C).
Moreover, the expression of the b2-integrin subunits
CD18, CD11a, and CD11b on classical monocytes was
reduced, suggesting an impaired recruitment-ability
(Figures 3D and 3E). Indeed, intravital microscopy of
the carotid artery of 14-week-old Apoe/ mice that
were fed an atherogenic diet for 6 weeks and treated
with TRAF-STOPs or control showed that 6877002 and
6860766 strongly reduced the recruitment of leuko-
cytes to the carotid arterial wall of Apoe/ mice
(Figures 3F and 3G).
In vitro monocyte migration assays using human
endothelial cells and human monocytes conﬁrmed the
decrease in monocyte recruitment upon TRAF-STOP
treatment (Figure 3H). When monocytes were treated
with TRAF-STOP 6877002 or 6860766, recruitment
was reduced by 30.5% and 49.9%, respectively
(Figure 3H). However, when the endothelial cells were
treated with TRAF-STOPs, monocyte recruitment was
only slightly reduced by 6877002 (Figure 3H). A similar
phenomenon was observed in human umbilical vein
endothelial cells: TRAF-STOP treatment resulted in a
small, but signiﬁcant, reduction in vascular cell
adhesion molecule (VCAM)-1 and intercellular adhe-
sion molecule (ICAM)-1 expression, but did not affect
other endothelial activation markers such as inter-
leukin (IL)-6, IL-8, tumor necrosis factor (TNF)-a, and
C-C motif chemokine ligand 2 (CCL2) (Figure 3I).
Moreover, in ex vivo TRAF-STOP–treated aortas of
Apoe/ mice, VCAM-1 expression was not altered
(Figures 3J and 3K), suggesting that TRAF-STOPs pre-
dominantly affect myeloid cells.
TRAF-STOPs REDUCE MACROPHAGE ACTIVATION.
TRAF-STOP treatment attenuates the inﬂammatory
propensity of macrophages. The CD40-induced
expression of TNF-a, IL-1b, IL-6, IL-10, IL-12, and
inducible nitric oxide synthase (iNOS) was reduced inFIGURE 1 Continued
(A) Twelve-week-old male Apoe/ mice were fed a normal chow diet
6860766 (n ¼ 12) (10 mmol/kg/day in 200 ml of vehicle), or vehicle c
dimethylsulfoxide) (n ¼ 15). (B) Atherosclerotic plaque area of the aor
sclerotic plaques were classiﬁed by phenotype, intimal xanthoma (IX),
revealing less FCA after TRAF-STOP treatment. (D) Representative ima
sections of plaques in the aortic arch (AA), including the brachiocephal
(LSA) (left panel, scale bar ¼ 2 mm), and plaques in the brachiocepha
control-treated Apoe/ mice showing a decrease in plaque size after TR
of Mac3þ macrophages (scale bar ¼ 70 mm) (E), CD3þ T cells (scale bar
shown in these representative pictures of atherosclerotic plaques of th
receptor-associated factors.TRAF-STOP 6877002- and 6860766-treated bone
marrow-derived macrophages (BMDMs) (Figure 4A).
In accordance, the chemokine-chemokine receptor
pairs CCL2-CCR2 and CCL5-CCR5 exhibited a similar
decrease (Figure 4B), which was consistent with a
reduction in CD40-induced chemotaxis of BMDMs
(Figure 4C).
In addition to its anti-inﬂammatory effects, TRAF-
STOPs reduced CD36 expression (Figure 4D), resulting
in a decreased uptake of oxidized low-density lipo-
protein (Figure 4E) and a reduction in macrophage
foam cell formation (Figure 4F). Neither phagocytosis
or efferocytosis nor the expression of the reverse
cholesterol transporters ABCA1 or ABCG1 were
affected by TRAF-STOP treatment (Online Figure 5).
These data suggest that TRAF-STOP treatment retards
foam cell formation by decreasing CD36-mediated
lipoprotein uptake.
To conﬁrm that TRAF-STOPs preferentially abolish
CD40-TRAF6 over CD40-TRAF2/3/5 signaling, we
activated BMDMs of CD40/, CD40þ/þ, CD40-Traf
wild type (Twt), CD40-T2/3/5/, and CD40-T6/
mice (15) with CD40-agonistic antibodies after pre-
incubation with the respective TRAF-STOPs. After
CD40 activation, CD40þ/þ, CD40-Twt, and CD40-T2/3/
5/ macrophages displayed a high expression of
CCL2. Yet, CCL2 was down-regulated in CD40/ and
CD40-T6/ macrophages, demonstrating a critical
role of CD40-TRAF6 interactions in regulating CCL2
levels (Figure 4G). Upon TRAF-STOP treatment, CCL2
levels decreased in CD40þ/þ, CD40-Twt, and CD40-
T2/3/5/ macrophages, suggesting that TRAF-STOPs
prevent the CD40-TRAF6–mediated increase in CCL2
(Figure 4G). Moreover, TRAF-STOP treatment did not
further decrease CCL2 expression in CD40/ and
CD40-TRAF6/ macrophages (Figure 4G), indicating
that TRAF-STOPs abolish CD40-TRAF6, and not
CD40-TRAF2/3/5, interactions.and were injected for 6 weeks with TRAF-STOP 6877002 (n ¼ 13),
ontrol (vehicle: phosphate-buffered saline, 0.05% Tween 80, 5%
tic arch had decreased after TRAF-STOP treatment. (C) Athero-
pathological intimal thickening (PIT), ﬁbrous cap atheroma (FCA),
ges (hematoxylin and eosin–stained sections) of longitudinal
ic trunk (BCT), left carotid artery (LCA), and left subclavian artery
lic trunk (right panel, scale bar ¼ 100 mm) of TRAF-STOP- and
AF-STOP treatment. TRAF-STOP treatment decreases the amount
¼ 40 mm) (F), and Ly6Gþ neutrophils (scale bar ¼ 50 mm) (G), as
e brachiocephalic trunk. *p < 0.05. TRAF ¼ tumor necrosis factor
FIGURE 2 TRAF-STOP Treatment Reduces the Progression of Established Atherosclerosis and Induces a Stable Plaque Phenotype
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(A) Twenty-two-week-old male Apoe/ mice were fed a normal chow diet and were injected for 6 weeks with TRAF-STOP 6877002 (n ¼ 12), 6860766
(n ¼ 11) (10 mmol/kg/day in 200 ml of vehicle), or vehicle control (phosphate-buffered saline, 0.05% Tween 80, 5% dimethylsulfoxide) (n ¼ 11).
(B) Atherosclerotic plaque area of established lesions of the aortic arch had decreased after TRAF-STOP treatment; representative pictures of plaques of
the brachiocephalic trunk (scale bar ¼ 100 mm). TRAF-STOP treatment decreases the amount of Mac3þ macrophages (scale bar ¼ 100 mm) (C), the
fraction of Ki67þ proliferating cells (scale bar ¼ 50 mm) (D), and the lipid core content of the atherosclerotic plaque (scale bar ¼ 100 mm) (E), and
increases the percentage of SRþ plaque collagen content (scale bar ¼ 100 mm) (F) showing that TRAF-STOP treatment not only slows down the pro-
gression of established atherosclerotic plaques, but also induces atherosclerotic plaque stabilization. HE ¼ hematoxylin and eosin. *p < 0.05.
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FIGURE 3 TRAF-STOP Treatment Reduces Leukocyte Recruitment
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(A) TRAF-STOP 6877002 reduced the frequency of CD40high classical monocytes (CD45þCD11bþLy6G-Ly6Chigh) in the spleen, whereas nonclassical
monocytes (CD45þCD11bþLy6G-Ly6Clow) were not affected (n ¼ 3). (B and C) TRAF-STOP 6877002 reduced the overall expression of CD40 on classical
monocytes, but not on nonclassical monocytes (n ¼ 3). (D and E) The expression of the b2-integrin subunits CD18, CD11a, and CD11b on classical
monocytes was reduced by TRAF-STOP; this decrease was not observed in nonclassical monocytes (n ¼ 3). (F) Intravital microscopy of the carotid artery
in 14-week-old Cx3cr1egfp/wtApoe/ mice fed a high-fat diet for 6 weeks (n ¼ 5 to 8 per group). To visualize neutrophils, an antibody to Ly6G was
instilled. (G) After the initial recordings, leukocytes were stained by rhodamine 6G administration. Leukocyte adhesion to the endothelium was reduced
in 6877002-treated and 6860766-treated Apoe/ mice (scale bar ¼ 2 mm). In particular, monocyte and neutrophil adhesion was impaired in
TRAF-STOP–treated mice (n ¼ 5 to 8 per group). (H) An in vitro migration assay demonstrated that TRAF-STOP treatment of monocytes markedly
reduced monocyte migration, whereas treatment of endothelial cells (ECs) with TRAF-STOP 6877002 had a minor effect. (I) HUVECs (human umbilical
vein endothelial cells) were activated using the CD40-agonistic antibody G28.5. TRAF-STOP 6877002 and 6860766 reduced the expression of the
cell adhesion molecules intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 (n ¼ 3 experiments). (J and K) Ex vivo 2-
photon microscopy in aortas of Apoe/ mice (n ¼ 6 to 9) revealed that the en face expression of VCAM did not differ between control and TRAF-STOP
6877002-treated endothelium. VCAM-1 expression was analyzed using labeled-antibodies. *p < 0.05, **p < 0.01, ***p < 0.001. CCL2 ¼ C-C motif
chemokine ligand 2; IL ¼ interleukin; MFI ¼ mean ﬂuorescence intensity; TNF ¼ tumor necrosis factor.
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534Next, we analyzed the effects of 6877002 and
6860766 on the activation of CD40-induced signaling
intermediates of the canonical and noncanonical nu-
clear factor kappa-light-chain-enhancer of activated B
cells (NF-kB) pathways and ERK1/2 signaling in
BMDMs. Both TRAF-STOPs reduced the CD40-
induced phosphorylation of Tak1 and NF-kB p65
(Figures 4H to 4J), whereas the levels of NF-kB2 p52
and the phosphorylation of ERK1/2 were not affected
(Figures 4H, 4K, and 4L). These results indicate that
TRAF-STOPs speciﬁcally inhibit the canonical NF-kB
pathway, and not the noncanonical NF-kB pathway or
ERK1/2 signaling.
To unravel further transcriptional changes upon
TRAF-STOP treatment, BMDMs from C57Bl6 mice
were treated with either of the 2 TRAF-STOPs
and activated with a CD40 agonistic antibody.
As expected, transcriptional analysis (Illumina, San
Diego, California) comparing TRAF-STOP–treated
BMDMs with control-treated cells and subsequent
Ingenuity Pathway Analysis (Qiagen, Hilden, Ger-
many) revealed “immune reactions” as the most
highly affected pathways for both TRAF-STOPs
(Online Figures 6A and 6B). Moreover, other top-
ranking pathways were cholesterol biosynthesis
(6860766 and 6877002), and/or cell cycle progression
(only 6877002) (Online Figures 6A and 6B, Online
Tables 1 and 2). Validation by quantitative polymer-
ase chain reaction conﬁrmed that TRAF-STOPs reduce
the expression of cholesterol biosynthesis genes,
including acat2, hmgcr, cyp51, sqle, mvd, and dhcr24
(Online Figures 6C and 6D).
Because Ingenuity Pathway Analysis revealed that
TRAF-STOP 6877002, but not 6860766, affected cell
cycle–related pathways in BMDMs (Online Figures 6A
and 6B, Online Tables 1 and 2), we further analyzed
this phenomenon. TRAF-STOP 6877002, but not
6860766, did reduce macrophage proliferation in
atherosclerotic plaques, as measured by Ki67 immu-
nohistochemistry, and reduced the expression of Ki67
in BMDMs, suggesting reduced proliferation of these
cells (Figures 2C and 2D, Online Figures 3N and 6E).
However, TRAF-STOP 6877002 also increased the
expression of cyclin D1, the regulator of CDK4 and
CDK6, crucial for G1/S transition (Online Figure 6E).
These results suggest that TRAF-STOP 6877002 may
affect certain aspects of cell cycle progression, but
that these effects are minor compared to the effects
on inﬂammation.
The different effects on cell cycle parameters
suggest that TRAF-STOP 6877002 and 6860766
have a slightly different mode of action (OnlineFigures 6A and 6B). Using several docking strate-
gies and binding studies using mutant TRAF6 pro-
tein, we could indeed prove that 6877002 and
6860766 interact with the TRAF6 C-terminus in a
different conformation (Online Figure 7, Online
Table 3).
TRAF-STOP TREATMENT DOES NOT IMPAIR
CLASSICAL CD40-MEDIATED IMMUNE RESPONSES.
Antibody-mediated inhibition of CD40 results in
immunosuppression because it impairs CD40-
mediated immune responses, including immuno-
globulin isotype switching, germinal center
formation, dendritic cell (DC)-mediated cos-
timulation, and lymphocyte activation (12). We
investigated whether TRAF-STOP treatment cau-
ses any of these CD40-inhibition–associated side
effects.
Immunoglobulin levels were analyzed in the
plasma of 28-week-old Apoe/ mice that were
treated with TRAF-STOPs for 6 weeks. No differ-
ences in IgM, IgG, and IgG subtype levels were
detected (Figures 5A and 5B). Histological analysis
of the spleen showed normal germinal center for-
mation in TRAF-STOP–treated animals (Figure 5C).
To address the effect of TRAF-STOPs on antigen-
speciﬁc immunoglobulin responses, C57Bl6 mice
were vaccinated with myelin oligodendrocyte glyco-
protein peptide (MOG35-55) and immunoglobulin levels
were measured. TRAF-STOP treatment did not
affect IgM, IgG, IgG1, IgG2b, IgG2c, IgG3, or antigen-
speciﬁc anti-MOG IgG levels (Figures 5D and 5E),
indicating that TRAF-STOP treatment does not inter-
fere with the role of CD40 signaling in Ig isotype
switching.
To elucidate the effects of TRAF-STOPs on DC-
mediated costimulation of T cells, ovalbumin pep-
tide (OVA323)-loaded DCs were matured, treated with
6877002 or 6860766, and cocultured with OTII-
transgenic CD4þ T cells. TRAF-STOPs did not affect
antigen-speciﬁc T-cell proliferation (Figure 5F), indi-
cating that DCs maintained their antigen presenting
capabilities and were able to induce T-cell
proliferation.
To test the effects of TRAF-STOPs on lymphoid cell
activation, T cells (Jurkat cells) and B cells (CA46
cells) were incubated with TRAF-STOPs and,
depending on the cell type, activated with a CD40
agonistic antibody (G28.5) and/or lipopolysaccharide,
TNFa, or CD3/CD28 beads. This revealed that TRAF-
STOPs had only minor effects on the activation sta-
tus of T and B cells (Figures 5G and 5H).
FIGURE 4 TRAF-STOP Target Macrophage Activation
Control 6877002 6860766
120
100
* *80
CD
36
 (M
FI
, %
 o
f C
on
tr
ol
)
60
40
20
0
Co
ntr
ol
68
77
00
2
68
60
76
6
120
100
* **80
Di
l-o
xL
DL
 (M
FI
, %
 o
f C
on
tr
ol
)
60
40
20
0
Co
ntr
ol
68
77
00
2
68
60
76
6
120
100
*
*80
OR
O
+ 
Ce
lls
 (%
 o
f T
ot
al
 C
el
ls
)
60
40
20
0
Co
ntr
ol
68
77
00
2
68
60
76
6
15
CC
L2
 m
RN
A 
(A
U) 10
5
0
C5
7B
I6
CD
40
–/–
CD
40
-Tw
t
CD
40
-T2
/3/
5–
/–
CD
40
-T6
–/–
10 **
***
M
ig
ra
tio
n 
(%
 o
f u
ns
tim
ul
at
ed
 c
el
ls
)
5
0
-5
Control 6877002 6860766
60000
40000
20000
2000
1000
200
** ** ***
***
* *
*
*****
***
m
RN
A 
(A
U)
100
0
TNFα IL1β IL6 IL10 IL12 iNOS
12
*
**
* ** * *** **
10
8
6
4
3m
RN
A 
(A
U)
2
1
0
CCL2 CCR2 CCR5CCL5
3
pT
ak
1/
α
Tu
bu
lin 2
1
0
Co
ntr
ol
68
77
00
2
68
60
76
6
Co
ntr
ol
68
77
00
2
68
60
76
6
10 Minutes 24 Hours
4
pN
F-
κB
2 
p5
2/
p1
00
2
3
1
0
Co
ntr
ol
68
77
00
2
68
60
76
6
Co
ntr
ol
68
77
00
2
68
60
76
6
10 Minutes 24 Hours
5
4
pE
RK
/E
RK
2
3
1
0
Co
ntr
ol
68
77
00
2
68
60
76
6
Co
ntr
ol
68
77
00
2
68
60
76
6
10 Minutes 24 Hours
12
pN
F-
κB
p6
5/
NF
κB
p6
5
8
4
2
0
Co
ntr
ol
68
77
00
2
68
60
76
6
Co
ntr
ol
68
77
00
2
68
60
76
6
10 Minutes 24 Hours
pTak1
10 Minutes 24 Hours
un
st
im
ul
at
ed
co
nt
ro
l
co
nt
ro
l
68
77
00
2
68
60
76
6
68
77
00
2
68
60
76
6
αTubulin
αTubulin
αTubulin
pNF-κBp65
NF-κBp65
NF-κB2p100
NF-κB2p52
β—actin
pERK1/2
pERK1/2
A
D
H I J
K L
E F G
B C
*
*
* *
*
* *
*
** **
**
*
** **
*** ***
TRAF-STOP 6877002 and 6860766 reduced the CD40-induced mRNA expression of cytokines (A) and chemokines (B) in BMDMS (bone marrow-derived macrophages)
(n ¼ 3 experiments with triplicates). (C) TRAF-STOPs hampered the CD40-induced migration of BMDMs in a chemotaxis assays (n ¼ 12). CD36 expression (n ¼ 10) (D)
and Bodipy–oxidized low-density lipoprotein uptake (n ¼ 5) (E) in BMDMs decreased after TRAF-STOP treatment, as measured by ﬂow cytometry. (F) Foam cell
formation, indicated by Oil Red O staining, was reduced after TRAF-STOP treatment (n ¼ 5). Antibody-mediated activation of CD40 induced CCL2 expression in
CD40þ/þ, CD40-Twt, and CD40-T2/3/5/ BMDMs, but not in CD40/ and CD40-T6/ macrophages (n ¼ 3 experiments). (G) TRAF-STOPs inhibited the CD40-
induced expression of CCL2 in CD40þ/þ, CD40-Twt, and CD40-T2/3/5/ macrophages and had no additional effect in CD40/ and CD40-T6/ macrophages. (H)
Western blot analysis of the CD40-induced signaling intermediates of the canonical and noncanonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB) pathways and ERK1/2 signaling in BMDMs (n ¼ 2 to 3). Both TRAF-STOPs reduced the phosphorylation of Tak1 (I) and the NF-kB p65 subunit (J) upon antibody-
mediated activation of CD40 in BMDM. TRAF-STOPs did not affectNF-kB2p52 levels (K) and phosphorylation of ERK1/2 (L). *p<0.05, **p<0.01, ***p<0.001. iNOS¼
inducible nitric oxide synthase; mRNA ¼messenger ribonucleic acid; other abbreviations as in Figure 3.
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FIGURE 5 TRAF-STOPs Do Not Impair Classical CD40-Mediated Immune Responses
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537Because interference with the CD40 pathway may
also affect acute antibacterial immune responses,
TRAF-STOP–treated C57Bl6 mice were subjected to
Escherichia coli-induced peritonitis and bacterial
outgrowth was analyzed in the peritoneal lavage
ﬂuid, lungs, liver, and blood. TRAF-STOP 6860766
reduced bacterial load in the lungs and peritoneal
ﬂuid, whereas 6877002 had no effect (Figure 5I),
indicating that anti-bacterial responses were not
affected.
Collectively, these experiments demonstrate that
TRAF-STOPs do not impair the classical CD40-
mediated immune responses, indicating that these
inhibitors have the potential to overcome the current
limitations of CD40 targeting antibodies.
MACROPHAGE-SPECIFIC TARGETING OF TRAF-STOPs
VIA RECOMBINANT HIGH-DENSITY LIPOPROTEIN
NANOTHERAPY. Although the TRAF-STOPs predomi-
nantly target myeloid cells, and do not seem to impair
CD40-mediated lymphocyte functions, we aimed to
even improve TRAF-STOP’s in vivo speciﬁcity for
macrophages by incorporating 6877002 in recombi-
nant high-density lipoprotein (rHDL) nanoparticles
(Figure 6A) (17,18).
Twenty-four hours after injection of DiR-labeled
rHDL-6877002 nanoparticles, we were able to show
localization of rHDL-6877002 in the liver and spleen
(Figure 6B), as well as in the aortic sinus region of
the aorta (Figure 6C). Flow cytometric analysis of
blood, spleen, and aorta showed that DiO-labeled
rHDL-6877002 was predominantly present in mac-
rophages, and to a lesser extent in monocytes and
neutrophils (Figure 6D), with the highestFIGURE 5 Continued
(A) TRAF-STOPs did not affect immunoglobulin M (IgM), IgG levels in
6 weeks (n ¼ 11 to 12). (B) IgG2b, IgG2c, and IgG3 ratios were not alt
enzyme-linked immunosorbent assay (ELISA) (n ¼ 11 to 12). (C) Repre
immunohistochemical staining of CD21 and Bcl6) of splenic germinal
center formation in 28-week-old Apoe/ mice that were treated for 6
C57Bl6 mice were vaccinated with myelin oligodendrocyte glycoprotein
were determined by ELISA (n ¼ 6 to 8 per group). TRAF-STOP treatm
IgG2c, and IgG3 ratios. Antigen-speciﬁc anti-MOG IgG levels at 16 an
treatment (n ¼ 8). (F) Coculture of TRAF-STOP–treated, ovalbumin p
transgenic CD4þ T cells demonstrated that T-cell proliferation was no
(n ¼ 6). (G) Jurkat T cells were activated using CD3/CD28 beads. TRA
expression of costimulatory molecules. (H) CA46 B-cells were activat
TRAF-STOP 6877002 and 6860766. No effects of TRAF-STOP on B-c
mice (n ¼ 8 per group) were treated with the TRAF-STOPs, and perit
Sixteen hours after inoculation the bacterial outgrowth in various tiss
outgrowth in the peritoneal lavage ﬂuid, lungs, liver and blood. *p <ﬂuorescence signal in aortic macrophages
(Figure 6D). Histological analysis conﬁrmed the
presence of DiO-rHDL-6877002 in atherosclerotic
plaque macrophages (Figure 6E).
Subsequently, Apoe/mice that were fed a normal
chow diet were treated twice a week with rHDL-
6877002 (10 mmol/kg) for the duration of 6 weeks,
starting at the age of 12 weeks (Figure 6A). Besides a
small increase in cholesterol levels and total leuko-
cyte counts, no abnormalities in body weight, hema-
tological parameters, and leukocyte subsets were
observed (Online Figures 8A to 8F). Although pro-
nounced uptake of rHDL-6877002 was observed in
the liver and spleen, we did not ﬁnd any signs of
hepatotoxicity or functional hyposplenism (Online
Figures 8G to 8J).
Atherosclerotic plaques were small, and only
intimal xanthomas and few pathological intimal
thickenings could be observed in the aortic root and
aortic arch region. However, plaque volume in
the aortic root had signiﬁcantly decreased upon
rHDL-6877002 treatment (Figure 6F), and plaques
contained fewer macrophages (Figure 6G). In this
initial stage, the number of CD3þ T cells, aSMC and
collagen content, proliferation, and apoptosis were
not affected. Compared with the administration of
the bare TRAF-STOPs, this nanomedicine-based
strategy allowed us to reduce the treatment fre-
quency and cumulative dosage.
DISCUSSION
Here, we show that blocking CD40-TRAF6 interactions
by SMI (TRAF-STOP) treatment strongly reducesthe plasma of 28-week-old Apoe/ mice that were treated for
ered by TRAF-STOPs. Immunoglobulin levels were determined by
sentative images (hematoxylin and eosin–stained sections and
centers demonstrated that TRAF-STOPs did not affect germinal
weeks (scale bar ¼ 100 mm) (n ¼ 12 to 15 per group). (D and E)
peptide (MOG35-55) and antigen-speciﬁc immunoglobulin levels
ent did not affect the levels of IgM and IgG, or the IgG1, IgG2b,
d 28 days after vaccination were not affected by TRAF-STOP
eptide-loaded dendritic cells (DCs) and CFSE-labeled, OTII
t affected. T-cell proliferation was assessed by ﬂow cytometry
F-STOP treatment did not affect T-cell cytokine expression nor
ed using the CD40-agonistic antibody G28.5 and treated using
ell activation could be detected (n ¼ 3 experiments). (I) C57Bl6
onitis was induced by intraperitoneal injection of Escherichia coli.
ues was analyzed. TRAF-STOP did not increase the bacterial
0.05, **p < 0.01. Abbreviations as in Figures 3 and 4.
FIGURE 6 rHDL-6877002 Nanoparticles Target Macrophages and Reduce the Initiation of Atherosclerosis
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539atherosclerosis by preventing activation of classical
monocytes, leukocyte recruitment, and macrophage
activation and migration in the arterial wall (Central
Illustration). Importantly, TRAF-STOP treatment not
only retarded the initiation of atherosclerosis, but
also reduced the progression of (established) athero-
sclerosis and stabilized existing atherosclerotic
plaques.
The costimulatory receptor/ligand dyad CD40-
CD40L is highly expressed in human atherosclerotic
lesions, and plays a pivotal role in atherosclerosis by
orchestrating the inﬂammatory response underlying
plaque development and progression (10,22). The
therapeutic potential of CD40-CD40L targeting
strategies is emphasized by the observation that
genetic or antibody-mediated inhibition of CD40L in
Apoe/ mice induced a plaque phenotype that is
low in inﬂammatory cell content and high in
ﬁbrosis, representing the clinically favorable stable
phenotype (11–14,23). However, until now, no treat-
ment options blocking CD40-CD40L in CVD were
available. Clinical trials, evaluating the efﬁcacy of
anti-CD40L antibodies, were halted due to the
occurrence of thromboembolic events (9,16).
Although antagonistic CD40 antibodies are available,
long-term antibody-mediated inhibition of CD40
results in immune suppression and is therefore not
feasible for the treatment of chronic diseases like
atherosclerosis (15,24).
Our newly developed TRAF-STOPs harbor the
potential for utilization in chronic inﬂammatory
diseases such as atherosclerosis, as classical CD40-
mediated immune responses including antigen-
speciﬁc T-cell proliferation and immunoglobulin
isotype switching are not impaired (15,24). We
observed no thromboembolic complications in
TRAF-STOP–treated mice, as these SMIs do not
interfere with the CD40L-aIIbb3 interaction and
hence do not induce destabilization of arterial
thrombi (16).FIGURE 6 Continued
(A) A schematic representation of rHDL-6877002, which was created by
MHPC [1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine]) and TRAF-
distribution in mouse organs (n ¼ 3), showing accumulation of DiR-rHDL
in mouse aorta (n ¼ 3), showing accumulation of DiR-rHDL-6877002 in
spleen, and whole mouse aortas (n ¼ 8) with DiO-labeled rHDL-687700
(E) Sections of the aortic root containing atherosclerotic plaques, showi
rHDL-6877002 is being taken up by plaque macrophages (colocalization
(scale bar ¼ 100 mm) (G) decrease after 6 weeks of rHDL-6877002 trea
rHDL ¼ recombinant high-density lipoprotein.TRAF-STOPs have the inherent characteristic of
reducing the recruitment and chemokine and cyto-
kine release of myeloid cells, while leaving the
remainder of the vascular-associated CD40-
expressing cells largely unaffected. This inherent
cell-type speciﬁcity reﬂects the CD40-TRAF in-
teractions that occur in the different cell types. In
monocytes and macrophages, the interaction of
CD40 with TRAF6, but not with TRAF2 is essential to
induce proinﬂammatory pathways (25). In mono-
cytes/macrophages, TRAF6 acts as a critical adaptor
of both the Src/ERK1/2 and IKK/NFkB signaling
pathways (25). In B cells, CD40-TRAF6 interactions
promote canonical NF-kB signaling via activation of
transforming growth factor (TGF)-b activated kinase
(TAK), and CD40-TRAF6 interactions are needed for
afﬁnity maturation and the generation of long-lived
plasma cells (15). However, for normal B-cell func-
tion, CD40-TRAF2 interactions are more crucial (24).
Mouse studies indeed showed that CD40-TRAF2, but
not CD40-TRAF3 or -6 interactions are essential for
germinal center formation, and that CD40-TRAF2
activation and TRAF3 degradation are more crucial
for CD40-induced B-cell activation than CD40-
TRAF6 interactions (15,26). The divergent CD40-
TRAF interactions in B cells may thus explain the
limited effects of our CD40-TRAF6 SMI on B-cell
activation, immunoglobulin isotype switching, and
germinal center formation observed in our study.
CD40 is also expressed on endothelial cells, and its
activation induces expression of cell adhesion mol-
ecules and promotes leukocyte adhesion (10,17).
Upon CD40 activation, aortic endothelial cells pro-
duce CX3CL1 and TNF-a, and this process is depen-
dent on both CD40-TRAF2 and CD40-TRAF6
interactions (27). Interestingly, TRAF3 can prevent
CD40-mediated endothelial cell activation (28). Our
data show that TRAF-STOP treatment of endothelial
cells can induce a minor reduction in VCAM-1
and ICAM-1 expression as well as macrophagecombining human apoA-I, lipids (DMPC [1,2-dimyristoyl-sn-glycero-3-phosphorylcholine] and
STOP 6877002. (B) Near infrared ﬂuorescence (NIRF) imaging of DiR-labeled rHDL-6877002
-6877002 in the liver and spleen. (C) NIRF imaging of DiR-labeled rHDL-6877002 distribution
the aortic root area, a region containing atherosclerosis. (D) Flow cytometry data of blood,
2, showing rHDL accumulation in macrophages and monocytes, especially in the aorta.
ng DiO-labeled rHDL-6877002 (red) and F4/80þ macrophages (green), revealing that
, yellow). Plaque volume (scale bar ¼ 200 mm) (F) and the number of plaque macrophages
tment (n ¼ 8) compared with rHDL treatment (n ¼ 8). *p < 0.05. ApoA ¼ apolipoprotein A;
CENTRAL ILLUSTRATION TRAF-STOP Treatment Reduces Atherosclerosis and Preserves Immunity
Seijkens, T.T.P. et al. J Am Coll Cardiol. 2018;71(5):527–42.
Binding of CD40L to CD40 results in the recruitment of tumor necrosis factor receptor-associated factors (TRAFs), and propagation of signaling. The C-terminal part of
CD40 contains a TRAF2/3/5 binding domain and a TRAF6 binding domain that both induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)
transcription. CD40-TRAF6 interactions are the predominant signal transduction route in macrophages, and are important in atherosclerosis, whereas CD40-TRAF2/3/5
interactions are important in CD40 driven immunity in other cell types, including dendritic cells (DCs) and B cells. Small molecule inhibitors of the CD40-TRAF6
interactions (TRAF-STOPs) inhibit CD40-induced activation of the canonical NF-kB pathway and subsequent cytokine and chemokine production. TRAF-STOPs are
particularly effective in monocytes/macrophages and hamper monocyte recruitment, macrophage activation, and foam cell formation. Consequently, both de novo
and established atherosclerosis are reduced upon TRAF-STOP treatment. By keeping CD40-TRAF2/3/5 interactions intact, CD40-mediated immunity is preserved, and
immune suppressive side effects are prevented. MHC ¼ major histocompatibility complex; TCR ¼ T cell receptor.
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540recruitment in vitro, but does not affect VCAM-1
expression ex vivo.
Although TRAF-STOPs intrinsically target macro-
phage function and have no effects on classical CD40immune responses, we cannot exclude the possibility
that systemic long-term administration will have
undesired effects on other cell types. Therefore, we
exploited the possibility of using a nanotherapeutic
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Blocking
CD40-CD40L interactions can reduce atherosclerosis and
converts vulnerable plaques into stable plaques in laboratory
models, but is not therapeutically viable because inhibition
compromises long-term systemic immune responses. Two small
molecule inhibitors that selectively block CD40-TRAF6 interac-
tions (TRAF-STOPs) reduce established atherosclerosis but
preserve immunity and have potential therapeutic value.
TRANSLATIONAL OUTLOOK: Clinical studies are needed to
establish the safety and efﬁcacy of targeted delivery of selective
CD40-TRAF6 inhibitors to plaque macrophages through high-
density lipoprotein nanoparticles.
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541approach; TRAF-STOP 6877002 was packaged into
rHDL, which has a high afﬁnity for macrophages, and
is not taken up by lymphoid cells (29,30). Indeed,
rHDL-6877002 speciﬁcally targets macrophages, and
prevents plaque initiation, requiring less frequent
drug administration and a lower cumulative dosage
compared with TRAF-STOP treatment. These results
show that nanotherapeutic delivery of TRAF-STOPs is
promising.
STUDY LIMITATIONS. Here we showed that TRAF-
STOPs successfully reduced both de novo and
established atherosclerosis in Apoe-/- mice. Further
pharmacological and toxicological studies are
required before the “ﬁrst in human” application of
TRAF-STOPs.
CONCLUSIONS
We have identiﬁed and characterized a group of SMI
of the CD40-TRAF6 interaction that successfully
reduce (existing) atherosclerosis by hampering
chemokine-mediated leukocyte recruitment to the
arterial wall and inhibiting cytokine secretion by
macrophages. These inhibitors will undoubtedly
require further development and reﬁnement before
they can be applied in a clinical setting. However, our
newly identiﬁed TRAF-STOPs can overcome thecurrent limitations of long-term CD40 and CD40L
inhibition in atherosclerosis and potentially in other
inﬂammatory diseases.
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